Who We Are

Biosensors develops, manufactures and markets innovative medical devices for interventional cardiology and critical care procedures.

Performance

Risk Assessment

Conclusion

Our Milestones
1990 2005 2007 2008 2010 2011 Company Founded Listed on SGX Mainboard Acquired 50% interest in JWMS Received CE Mark for BioMatrix Launched in Europe and Asia Hony Capital acquired majority stake in Biosesor Raised S$200 million (Alantis & Ever Union) Fully acquired JWMS

Performance

Risk Assessment

Conclusion

Our Presence

More about us
  Market Capitalisation: S$2.25 billion   Major shareholders:
         
Shandong Weigao Hony Capital Fidelity Atlantis EverUnion

  Total shares issued: 1.717 billion shares
Performance Risk Assessment Conclusion

Management Team
  Yoh Chie Lu, founder and Chairman
  President of Asia-Pacific division for BOC

  Jeffrey Jump & Jack Wang, Co-CEO
  Over 30 years experience

  John E. Shulze, Chief Technical Officer
  Primary architect of BioMatrix

  Ronald H. Ede, Chief Financial Officer
Performance Risk Assessment Conclusion

Growing DES Industry
Vascular Interventional Devices Market
DES

76%

Others

Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 – 2016) Global Trends & Competitive Analysis Report Code: MD 1752

Introduction

Risk Assessment

Conclusion

Growing DES Industry
Revenue Generated for Global DES Market (US$ Billion)
13.7 15 10 5 0 2011 2016
Source: Peripheral Vascular & Interventional Cardiology Devices Market (2011 – 2016) Global Trends & Competitive Analysis Report Code: MD 1752

8.9

Introduction

Risk Assessment

Conclusion

Our Business Model
Sales and Marketing Expenses Research and Development (R&D) General and Administrative Expenses Other operating expenses Introduction Risk Assessment Conclusion

Abluminal Coating Biolimus A9

S-Stent Platform Biodegradable Polymer

Competitive Edge
  The First Biodegradable DES - BioMatrix™   Strong clinical trial results   Access to China’s emerging market – JWMS   Next generation of DES- BioFreedom™   Strategic acquisition for technology development   CardioMind Inc.   AXXESSTM (Devax, Inc.)
Introduction Risk Assessment Conclusion

Financial Highlights
Revenue EPS

34.79%
Profit ROE

32.60%

34.98%
Introduction

48.42%
Risk Assessment Conclusion

Liquidity: High
GEARING RATIO COMPARISON
60 50 40 30 20 10 0 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 20.18 9.08 45.19 48.11 48.11 48.14 48.14 37.53 37.53 6.00 5.00 4.00 3.00 2.07 2.00 1.00 0.00 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 1.06 1.52 2.17 1.39 2.37 1.72

CURRENT RATIO COMPARISON
5.35

1.92

Introduction

Risk Assessment

Conclusion

ROE Comparison
ROE COMPARISON
25.00% 21.11% 20.00% 15.70% 15.00% 11.43% 10.00% 5.00% 0.00% -1.08% -5.00% -10.00% -15.00% BIOSENSORS BOSTON SCIENTIFIC MEDTRONIC -8.66% 2009 2010 2011 3.88% 2.16% 19.39%

-9.07%

Introduction

Risk Assessment

Conclusion

Profitability and Efficiency
ASSET TURNOVER RATIO COMPARISON
0.7000 0.6000 0.5000 0.4000 0.3000 0.2000 0.1000 0.0000 2009 BIOSENSORS 2010 BOSTON SCIENTIFIC 2011 MEDTRONIC 0.3252 0.3528 0.3580 0.3276 0.5993 0.6189 0.5101 0.5631 0.5237

NET PROFIT MARGIN COMPARISON
30.00% 25.00% 20.00% 15.00% 10.00% 5.00% 0.00% -5.00% -10.00% -15.00% -20.00% -13.01% -13.13% BOSTON SCIENTIFIC MEDTRONIC -0.94% 2009 2010 2011 14.18% 5.79% 27.59% 19.59% 27.63% 19.43%

BIOSENSORS

Introduction

Risk Assessment

Conclusion

Growth Strategy
  Expanding in China   JW Medical Service   Growing market   Penetrating the United States   Largest global DES market   Expanding Product Portfolio

Introduction

Risk Assessment

Conclusion

Risk Assessment
  Preferred supplier agreements   Declining prices of DES   Competition from local manufacturers   Regulatory Requirement

Introduction

Performance

Conclusion

3 Reasons to Invest
  We make dollars and stents   Every 2 seconds someone has a heart attack   Access to growing markets

Introduction

Performance

Q&A

Sign up to vote on this title
UsefulNot useful

Master Your Semester with Scribd & The New York Times

Special offer for students: Only $4.99/month.

Master Your Semester with a Special Offer from Scribd & The New York Times

Cancel anytime.